<!DOCTYPE html><html lang="en-us" >


<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  
  
  
    <meta name="generator" content="Wowchemy 5.4.0 for Hugo" />
  

  
  









  




  
  
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  

  
  
  
    
      
      <link rel="preload" as="style" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap">
      <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap" media="print" onload="this.media='all'">
    
  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="PURPOSE: To assess the onset, treatment frequency, and visual outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment due to secondary choroidal neovascularization (CNV) in patients with pseudoxanthoma elasticum (PXE). DESIGN: Retrospective cohort study METHODS: One-hundred six eyes of 53 patients with PXE were analyzed. The assessment of CNV activity relied on hemorrhage visible on funduscopy and intra- / subretinal fluid on optical coherence tomography (OCT), individually defining a shortening or extension of treatment interval. Best-corrected visual acuity (BCVA) at baseline, age at anti-VEGF therapy initiation, and BCVA-drop events at exudation onset (worsening of BCVA of 2 or more lines) were documented. Further, we assessed the number of injections during the first year and the total number of injections, the time to treatment initiation of the fellow eye, and BCVA over time. RESULTS: During a median observation period of 77 months (IQR 49; 126) patients received a median number of 28.0 anti-VEGF-injections (IQR 9.8; 43.5). Eight patients received no injection (median age at baseline 38.1 years), 11 patients underwent anti-VEGF treatment in one eye (median age 47.2 years) and 34 patients in both eyes (median age 51.8 years). The median age at the first anti-VEGF treatment was 52.80 years (IQR 47.2-57.6). Applying Cox regression models, the median ``survival&#39;&#39; time of fellow eye until treatment initiation was 16.8 months. In the group of bilateral treated patients, the median time difference was 9.6 months (IQR 2.1- 32.4, range 0-122) The median number of injections was 5.5 per eye in the first year of treatment (IQR 3-7) and was associated with the total number of injections in the observation period (2.33, CI 1.22-3.44, P &lt; .001). A better BCVA at the last follow-up visit was associated with a better baseline BCVA (P &lt; .001, R2 = 0.318) and with the absence of a BCVA drop at the onset of exudation (P = 0.035, R2 = 0.339). CONCLUSIONS: The results of this study indicate that anti-VEGF treatment is required for most PXE patients at a relatively young age. Once treatment in one eye is initiated, the time to fellow eye treatment is relatively short. A BCVA drop before treatment initiation is a risk factor for worse visual outcomes, suggesting that treatment is prudent before exudation affects the central retina. Given the young age of onset and intensive treatment needs, patients with PXE might particularly benefit from longer-acting anti-VEGF therapeutics." />

  
  <link rel="alternate" hreflang="en-us" href="https://pfaulab.com/publication/raming-2024-td/" />

  
  
  
    <meta name="theme-color" content="#1565c0" />
  

  
  

  

  <link rel="stylesheet" href="/css/vendor-bundle.min.f1ecf783c14edc00c9320c205831ad8e.css" media="print" onload="this.media='all'">

  
  
  
    
    

    
    
    
    
      
      
    
    
    

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/styles/github.min.css" crossorigin="anonymous" title="hl-light" media="print" onload="this.media='all'">
          <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" media="print" onload="this.media='all'" disabled>
        
      
    

    
    
    
      <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/leaflet@1.7.1/dist/leaflet.min.css" integrity="" crossorigin="anonymous" media="print" onload="this.media='all'">
    

    

    
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      
        
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
  

  
  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.512574799414e7d36471486881070b0f.css" />

  




<script async src="https://www.googletagmanager.com/gtag/js?id=G-MJX7QL4CZN"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'G-MJX7QL4CZN', {});
  gtag('set', {'cookie_flags': 'SameSite=None;Secure'});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  

  

  




  
  
  

  

  
    <link rel="manifest" href="/manifest.webmanifest" />
  

  <link rel="icon" type="image/png" href="/media/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_32x32_fill_lanczos_center_3.png" />
  <link rel="apple-touch-icon" type="image/png" href="/media/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_180x180_fill_lanczos_center_3.png" />

  <link rel="canonical" href="https://pfaulab.com/publication/raming-2024-td/" />

  
  
  
  
  
  
  
  
    
    
  
  

  
  
    
    
  
  <meta property="twitter:card" content="summary" />
  
  <meta property="og:site_name" content="Pfau Lab" />
  <meta property="og:url" content="https://pfaulab.com/publication/raming-2024-td/" />
  <meta property="og:title" content="Anti-VEGF treatment for secondary neovascularization in pseudoxanthoma elasticum - age of onset, treatment frequency, and visual outcome | Pfau Lab" />
  <meta property="og:description" content="PURPOSE: To assess the onset, treatment frequency, and visual outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment due to secondary choroidal neovascularization (CNV) in patients with pseudoxanthoma elasticum (PXE). DESIGN: Retrospective cohort study METHODS: One-hundred six eyes of 53 patients with PXE were analyzed. The assessment of CNV activity relied on hemorrhage visible on funduscopy and intra- / subretinal fluid on optical coherence tomography (OCT), individually defining a shortening or extension of treatment interval. Best-corrected visual acuity (BCVA) at baseline, age at anti-VEGF therapy initiation, and BCVA-drop events at exudation onset (worsening of BCVA of 2 or more lines) were documented. Further, we assessed the number of injections during the first year and the total number of injections, the time to treatment initiation of the fellow eye, and BCVA over time. RESULTS: During a median observation period of 77 months (IQR 49; 126) patients received a median number of 28.0 anti-VEGF-injections (IQR 9.8; 43.5). Eight patients received no injection (median age at baseline 38.1 years), 11 patients underwent anti-VEGF treatment in one eye (median age 47.2 years) and 34 patients in both eyes (median age 51.8 years). The median age at the first anti-VEGF treatment was 52.80 years (IQR 47.2-57.6). Applying Cox regression models, the median ``survival&#39;&#39; time of fellow eye until treatment initiation was 16.8 months. In the group of bilateral treated patients, the median time difference was 9.6 months (IQR 2.1- 32.4, range 0-122) The median number of injections was 5.5 per eye in the first year of treatment (IQR 3-7) and was associated with the total number of injections in the observation period (2.33, CI 1.22-3.44, P &lt; .001). A better BCVA at the last follow-up visit was associated with a better baseline BCVA (P &lt; .001, R2 = 0.318) and with the absence of a BCVA drop at the onset of exudation (P = 0.035, R2 = 0.339). CONCLUSIONS: The results of this study indicate that anti-VEGF treatment is required for most PXE patients at a relatively young age. Once treatment in one eye is initiated, the time to fellow eye treatment is relatively short. A BCVA drop before treatment initiation is a risk factor for worse visual outcomes, suggesting that treatment is prudent before exudation affects the central retina. Given the young age of onset and intensive treatment needs, patients with PXE might particularly benefit from longer-acting anti-VEGF therapeutics." /><meta property="og:image" content="https://pfaulab.com/media/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_3.png" />
    <meta property="twitter:image" content="https://pfaulab.com/media/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_3.png" /><meta property="og:locale" content="en-us" />
  
    
      <meta
        property="article:published_time"
        content="2024-07-19T21:41:22&#43;00:00"
      />
    
    <meta property="article:modified_time" content="2024-07-19T23:41:24&#43;02:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://pfaulab.com/publication/raming-2024-td/"
  },
  "headline": "Anti-VEGF treatment for secondary neovascularization in pseudoxanthoma elasticum - age of onset, treatment frequency, and visual outcome",
  
  "datePublished": "2024-07-19T21:41:22Z",
  "dateModified": "2024-07-19T23:41:24+02:00",
  
  "author": {
    "@type": "Person",
    "name": "Kristin Raming"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Pfau Lab",
    "logo": {
      "@type": "ImageObject",
      "url": "https://pfaulab.com/media/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_192x192_fill_lanczos_center_3.png"
    }
  },
  "description": "PURPOSE: To assess the onset, treatment frequency, and visual outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment due to secondary choroidal neovascularization (CNV) in patients with pseudoxanthoma elasticum (PXE). DESIGN: Retrospective cohort study METHODS: One-hundred six eyes of 53 patients with PXE were analyzed. The assessment of CNV activity relied on hemorrhage visible on funduscopy and intra- / subretinal fluid on optical coherence tomography (OCT), individually defining a shortening or extension of treatment interval. Best-corrected visual acuity (BCVA) at baseline, age at anti-VEGF therapy initiation, and BCVA-drop events at exudation onset (worsening of BCVA of 2 or more lines) were documented. Further, we assessed the number of injections during the first year and the total number of injections, the time to treatment initiation of the fellow eye, and BCVA over time. RESULTS: During a median observation period of 77 months (IQR 49; 126) patients received a median number of 28.0 anti-VEGF-injections (IQR 9.8; 43.5). Eight patients received no injection (median age at baseline 38.1 years), 11 patients underwent anti-VEGF treatment in one eye (median age 47.2 years) and 34 patients in both eyes (median age 51.8 years). The median age at the first anti-VEGF treatment was 52.80 years (IQR 47.2-57.6). Applying Cox regression models, the median ``survival'' time of fellow eye until treatment initiation was 16.8 months. In the group of bilateral treated patients, the median time difference was 9.6 months (IQR 2.1- 32.4, range 0-122) The median number of injections was 5.5 per eye in the first year of treatment (IQR 3-7) and was associated with the total number of injections in the observation period (2.33, CI 1.22-3.44, P \u003c .001). A better BCVA at the last follow-up visit was associated with a better baseline BCVA (P \u003c .001, R2 = 0.318) and with the absence of a BCVA drop at the onset of exudation (P = 0.035, R2 = 0.339). CONCLUSIONS: The results of this study indicate that anti-VEGF treatment is required for most PXE patients at a relatively young age. Once treatment in one eye is initiated, the time to fellow eye treatment is relatively short. A BCVA drop before treatment initiation is a risk factor for worse visual outcomes, suggesting that treatment is prudent before exudation affects the central retina. Given the young age of onset and intensive treatment needs, patients with PXE might particularly benefit from longer-acting anti-VEGF therapeutics."
}
</script>

  

  

  

  





  <title>Anti-VEGF treatment for secondary neovascularization in pseudoxanthoma elasticum - age of onset, treatment frequency, and visual outcome | Pfau Lab</title>
</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper   " data-wc-page-id="26df068d89b02a546c5ec5ee05f8183f" >

  
  
  
  
  
  
  
  
  
  <script src="/js/wowchemy-init.min.8f76bdc9e086322ed5147724ebba3d06.js"></script>

  


<aside class="search-modal" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#" aria-label="Close"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control"
        aria-label="Search...">
        
      </div>

      
      

      

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>



  <div class="page-header">
    












<header class="header--fixed">
  <nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
    <div class="container-xl">

      
      <div class="d-none d-lg-inline-flex">
        <a class="navbar-brand" href="/">Pfau Lab</a>
      </div>
      

      
      <button type="button" class="navbar-toggler" data-toggle="collapse"
              data-target="#navbar-content" aria-controls="navbar-content" aria-expanded="false" aria-label="Toggle navigation">
      <span><i class="fas fa-bars"></i></span>
      </button>
      

      
      <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
        <a class="navbar-brand" href="/">Pfau Lab</a>
      </div>
      

      
      
      <div class="navbar-collapse main-menu-item collapse justify-content-end" id="navbar-content">

        
        <ul class="navbar-nav d-md-inline-flex">
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#posts"><span>News</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#publications"><span>Publications</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#people"><span>Team</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#contact"><span>Contact</span></a>
          </li>

          
          

        

          
        </ul>
      </div>

      <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">

        
        

        
        

        
        

        
        

      </ul>

    </div>
  </nav>
</header>


  </div>

  <div class="page-body">
    








<div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>Anti-VEGF treatment for secondary neovascularization in pseudoxanthoma elasticum - age of onset, treatment frequency, and visual outcome</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  <span >
      <a href="/author/kristin-raming/">Kristin Raming</a></span>, <span >
      <a href="/author/maximilian-pfau/">Maximilian Pfau</a></span>, <span >
      <a href="/author/philipp-herrmann/">Philipp Herrmann</a></span>, <span >
      <a href="/author/frank-g-holz/">Frank G Holz</a></span>, <span >
      <a href="/author/kristina-pfau/">Kristina Pfau</a></span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    April 2024
  </span>
  

  

  

  
  
  
  
  
  

  
  

</div>

    




<div class="btn-links mb-3">
  
  








  





<a href="#" class="btn btn-outline-primary btn-page-header js-cite-modal"
        data-filename="/publication/raming-2024-td/cite.bib">
  Cite
</a>















</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">PURPOSE: To assess the onset, treatment frequency, and visual outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment due to secondary choroidal neovascularization (CNV) in patients with pseudoxanthoma elasticum (PXE). DESIGN: Retrospective cohort study METHODS: One-hundred six eyes of 53 patients with PXE were analyzed. The assessment of CNV activity relied on hemorrhage visible on funduscopy and intra- / subretinal fluid on optical coherence tomography (OCT), individually defining a shortening or extension of treatment interval. Best-corrected visual acuity (BCVA) at baseline, age at anti-VEGF therapy initiation, and BCVA-drop events at exudation onset (worsening of BCVA of 2 or more lines) were documented. Further, we assessed the number of injections during the first year and the total number of injections, the time to treatment initiation of the fellow eye, and BCVA over time. RESULTS: During a median observation period of 77 months (IQR 49; 126) patients received a median number of 28.0 anti-VEGF-injections (IQR 9.8; 43.5). Eight patients received no injection (median age at baseline 38.1 years), 11 patients underwent anti-VEGF treatment in one eye (median age 47.2 years) and 34 patients in both eyes (median age 51.8 years). The median age at the first anti-VEGF treatment was 52.80 years (IQR 47.2-57.6). Applying Cox regression models, the median ``survival'' time of fellow eye until treatment initiation was 16.8 months. In the group of bilateral treated patients, the median time difference was 9.6 months (IQR 2.1- 32.4, range 0-122) The median number of injections was 5.5 per eye in the first year of treatment (IQR 3-7) and was associated with the total number of injections in the observation period (2.33, CI 1.22-3.44, P &lt; .001). A better BCVA at the last follow-up visit was associated with a better baseline BCVA (P &lt; .001, R2 = 0.318) and with the absence of a BCVA drop at the onset of exudation (P = 0.035, R2 = 0.339). CONCLUSIONS: The results of this study indicate that anti-VEGF treatment is required for most PXE patients at a relatively young age. Once treatment in one eye is initiated, the time to fellow eye treatment is relatively short. A BCVA drop before treatment initiation is a risk factor for worse visual outcomes, suggesting that treatment is prudent before exudation affects the central retina. Given the young age of onset and intensive treatment needs, patients with PXE might particularly benefit from longer-acting anti-VEGF therapeutics.</p>
    

    
    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            <a href="/publication/#2">
              Journal article
            </a>
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>Am. J. Ophthalmol.</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    






<div class="article-tags">
  
  <a class="badge badge-light" href="/tag/bruchs-membrane-pxe-pseudoxanthoma-elasticum-anti-vegf/">Bruch&#39;s membrane; pxe; pseudoxanthoma elasticum; anti-vegf</a>
  
</div>













  
  
    




  
    




  
    




  
    




  
    




  














  
  





  </div>
</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">

  



  

  

  
  <p class="powered-by">
    © {2025} Maximilian Pfau
  </p>
  

  
  






  <p class="powered-by">
    
    
    
      
      
      
      
      
      
      Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target="_blank" rel="noopener">Wowchemy</a> — the free, <a href="https://github.com/wowchemy/wowchemy-hugo-themes" target="_blank" rel="noopener">open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

      

    
    <script src="/js/vendor-bundle.min.b73dfaac3b6499dc997741748a7c3fe2.js"></script>

    
    
    
      
      
        <script src="https://cdn.jsdelivr.net/gh/desandro/imagesloaded@v4.1.4/imagesloaded.pkgd.min.js" integrity="sha512-S5PZ9GxJZO16tT9r3WJp/Safn31eu8uWrzglMahDT4dsmgqWonRY9grk3j+3tfuPr9WJNsfooOR7Gi7HL5W2jw==" crossorigin="anonymous"></script>
        <script src="https://cdn.jsdelivr.net/gh/metafizzy/isotope@v3.0.6/dist/isotope.pkgd.min.js" integrity="sha512-Zq2BOxyhvnRFXu0+WE6ojpZLOU2jdnqbrM1hmVdGzyeCa1DgM3X5Q4A/Is9xA1IkbUeDd7755dNNI/PzSf2Pew==" crossorigin="anonymous"></script>
      

      
      

      

      
        
        <script src="https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/highlight.min.js" integrity="sha512-Ypjm0o7jOxAd4hpdoppSEN0TQOC19UtPAqD+4s5AlXmUvbmmS/YMxYqAqarQYyxTnB6/rqip9qcxlNB/3U9Wdg==" crossorigin="anonymous"></script>
        
        
        <script src="https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/languages/r.min.js" crossorigin="anonymous"></script>
        
        <script src="https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/languages/python.min.js" crossorigin="anonymous"></script>
        
        <script src="https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/languages/latex.min.js" crossorigin="anonymous"></script>
        
      

    

    
    
    
      <script src="https://cdn.jsdelivr.net/npm/leaflet@1.7.1/dist/leaflet.min.js" integrity="" crossorigin="anonymous"></script>
    

    
    

    
    
    
      
      <script id="search-hit-fuse-template" type="text/x-template">
        <div class="search-hit" id="summary-{{key}}">
          <div class="search-hit-content">
            <div class="search-hit-name">
              <a href="{{relpermalink}}">{{title}}</a>
              <div class="article-metadata search-hit-type">{{type}}</div>
              <p class="search-hit-description">{{snippet}}</p>
            </div>
          </div>
        </div>
      </script>
      
        <script src="https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js" integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin="anonymous"></script>
        <script src="https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js" integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin="anonymous"></script>
      
    

    
    

    
    
    
    

    
    
      
      
      
      
      
      
      
    

    

    
    
    
    <script id="page-data" type="application/json">{"use_headroom":true}</script>

    
    
      <script src="/js/wowchemy-headroom.1cb9e2fc8399acee94eab837265b73bf.js" type="module"></script>
    
    
    
    
    
    
    
      
      
    
    
    <script src="/en/js/wowchemy.min.247fd8f54253895301106e3006f53f38.js"></script>

    
  <script async defer src="https://buttons.github.io/buttons.js"></script>




</body>
</html>
